Ana Fakin1, Anthony G Robson1, John Pei-Wen Chiang2, Kaoru Fujinami3, Anthony T Moore4, Michel Michaelides1, Graham E Holder1, Andrew R Webster1. 1. Institute of Ophthalmology, University College London, London, United Kingdom 2Moorfields Eye Hospital, London, United Kingdom. 2. Casey Molecular Diagnostic Laboratory, Portland, Oregon, United States. 3. Institute of Ophthalmology, University College London, London, United Kingdom 2Moorfields Eye Hospital, London, United Kingdom 4National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan 5Department of Ophthalmology, Keio University, School of Medicine, Tokyo, Japan. 4. Institute of Ophthalmology, University College London, London, United Kingdom 2Moorfields Eye Hospital, London, United Kingdom 6Department of Ophthalmology, University of California-San Francisco School of Medicine, San Francisco, California, United States.
Abstract
PURPOSE: To determine the effect of 15 individual ABCA4 mutations on disease severity. METHODS: Eighty-two patients harboring 15 distinct ABCA4 mutations in trans with null (hemizygous), 10 homozygous, and 20 nullizygous patients were recruited. Age of onset was determined from medical histories. Electroretinography (ERG) responses were classified into three groups (normal; cone dysfunction; cone and rod dysfunction). The dark-adapted bright-flash (DA 10.0) a-wave amplitudes and the light-adapted flicker ERG (LA 3.0 30 Hz) amplitudes were plotted against age and compared with the nullizygous patients. Fundus autofluorescence imaging (FAF) was assessed when available. RESULTS: Patients hemizygous for p.G1961E and p.R2030Q had normal ERGs. Patients harboring p.R24H, p.R212C, p.G863A/delG, p.R1108C, p.P1380L, p.L2027F, and c.5714+5G>A had abnormal ERGs (ERG group 2 or 3) at older ages, in most cases with significantly higher amplitudes than nullizygous patients. Mutations p.L541P+A1038V, p.E1022K, p.C1490Y, p.E1087K, p.T1526M, and p.C2150Y were associated with abnormal ERGs (group 2 or 3) and amplitudes comparable to those of nullizygous patients. The majority of patients, including those harboring p.G1961E, had foveal atrophy; while both patients harboring p.R2030Q had foveal sparing. Most patients harboring intermediate and null-like mutations displayed FAF abnormalities extending beyond the vascular arcades. CONCLUSIONS: In the hemizygous state, 2/15 ABCA4 alleles retain preserved peripheral retinal function; 7/15 are associated with either preserved or only mildly abnormal retinal function, worse in older patients; 6/15 behave like null mutations. These data help characterize the degree of dysfunction conferred by specific mutant ABCA4 proteins in the human retina.
PURPOSE: To determine the effect of 15 individual ABCA4 mutations on disease severity. METHODS: Eighty-two patients harboring 15 distinct ABCA4 mutations in trans with null (hemizygous), 10 homozygous, and 20 nullizygous patients were recruited. Age of onset was determined from medical histories. Electroretinography (ERG) responses were classified into three groups (normal; cone dysfunction; cone and rod dysfunction). The dark-adapted bright-flash (DA 10.0) a-wave amplitudes and the light-adapted flicker ERG (LA 3.0 30 Hz) amplitudes were plotted against age and compared with the nullizygous patients. Fundus autofluorescence imaging (FAF) was assessed when available. RESULTS: Patients hemizygous for p.G1961E and p.R2030Q had normal ERGs. Patients harboring p.R24H, p.R212C, p.G863A/delG, p.R1108C, p.P1380L, p.L2027F, and c.5714+5G>A had abnormal ERGs (ERG group 2 or 3) at older ages, in most cases with significantly higher amplitudes than nullizygous patients. Mutations p.L541P+A1038V, p.E1022K, p.C1490Y, p.E1087K, p.T1526M, and p.C2150Y were associated with abnormal ERGs (group 2 or 3) and amplitudes comparable to those of nullizygous patients. The majority of patients, including those harboring p.G1961E, had foveal atrophy; while both patients harboring p.R2030Q had foveal sparing. Most patients harboring intermediate and null-like mutations displayed FAF abnormalities extending beyond the vascular arcades. CONCLUSIONS: In the hemizygous state, 2/15 ABCA4 alleles retain preserved peripheral retinal function; 7/15 are associated with either preserved or only mildly abnormal retinal function, worse in older patients; 6/15 behave like null mutations. These data help characterize the degree of dysfunction conferred by specific mutant ABCA4 proteins in the human retina.
Authors: Tjaša Krašovec; Marija Volk; Maja Šuštar Habjan; Marko Hawlina; Nataša Vidović Valentinčič; Ana Fakin Journal: Int J Mol Sci Date: 2022-07-02 Impact factor: 6.208
Authors: Esmee H Runhart; Patty Dhooge; Magda Meester-Smoor; Jeroen Pas; Jan Willem R Pott; Redmer van Leeuwen; Hester Y Kroes; Arthur A Bergen; Yvonne de Jong-Hesse; Alberta A Thiadens; Mary J van Schooneveld; Maria van Genderen; Camiel Boon; Caroline Klaver; L Ingeborg van den Born; Frans P M Cremers; Carel B Hoyng Journal: Acta Ophthalmol Date: 2021-08-25 Impact factor: 3.988
Authors: Yousra Falfoul; Imen Habibi; Ahmed Turki; Ahmed Chebil; Asma Hassairi; Daniel F Schorderet; Leila El Matri Journal: J Ophthalmol Date: 2018-03-15 Impact factor: 1.909
Authors: Salvador López-Rubio; Oscar F Chacon-Camacho; Rodrigo Matsui; Dalia Guadarrama-Vallejo; Mirena C Astiazarán; Juan C Zenteno Journal: Mol Vis Date: 2018-02-01 Impact factor: 2.367
Authors: Mubeen Khan; Gavin Arno; Ana Fakin; David A Parfitt; Patty P A Dhooge; Silvia Albert; Nathalie M Bax; Lonneke Duijkers; Michael Niblock; Kwan L Hau; Edward Bloch; Elena R Schiff; Davide Piccolo; Michael C Hogden; Carel B Hoyng; Andrew R Webster; Frans P M Cremers; Michael E Cheetham; Alejandro Garanto; Rob W J Collin Journal: Mol Ther Nucleic Acids Date: 2020-06-12 Impact factor: 8.886
Authors: Kaoru Fujinami; Rupert W Strauss; John Pei-Wen Chiang; Isabelle S Audo; Paul S Bernstein; David G Birch; Samantha M Bomotti; Artur V Cideciyan; Ann-Margret Ervin; Meghan J Marino; José-Alain Sahel; Saddek Mohand-Said; Janet S Sunness; Elias I Traboulsi; Sheila West; Robert Wojciechowski; Eberhart Zrenner; Michel Michaelides; Hendrik P N Scholl Journal: Br J Ophthalmol Date: 2018-06-20 Impact factor: 4.638